Boston University Libraries OpenBU
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    •   OpenBU
    • Theses & Dissertations
    • Boston University Theses & Dissertations
    • View Item
    •   OpenBU
    • Theses & Dissertations
    • Boston University Theses & Dissertations
    • View Item

    Reduction in maternal autoantibodies with intravenous immunoglobulin therapy during pregnancy

    Thumbnail
    Date Issued
    2019
    Author(s)
    Rocheleau, Danielle
    Share to FacebookShare to TwitterShare by Email
    Export Citation
    Download to BibTex
    Download to EndNote/RefMan (RIS)
    Metadata
    Show full item record
    Permanent Link
    https://hdl.handle.net/2144/38679
    Abstract
    The prevalence of autoimmune lupus has increased with the onset of disease typically occurring during the women’s reproductive years. As a result, many women are experiencing obstetric complications associated with lupus, including neonatal lupus (NL) syndrome. In particular, pregnant women who have elevated anti-Ro/SSA antibodies carry an increased risk of developing NL syndrome with the most serious complication being congenital complete heard block (CHB). Currently, there is no effective treatment for CHB and affected children often require cardiac pacemakers if they survive past delivery. Recent studies have shown an association between the concentration of anti-Ro/SSA antibodies and risk of fetal cardiac damage in NL. While the exact etiology of CHB is unknown, a therapeutic intervention aimed at reducing the concentration of these pathogenic antibodies may prevent the progression of cardiac NL in high risk pregnancies. This proposal is a pilot, double-blind, placebo-controlled randomized study assessing the effect of IVIG therapy on the change in concentration of maternal autoantibodies throughout pregnancy. Secondary outcomes will include 2nd and 3rd degree CHB. This study could potentially add to current evidence supporting the use of IVIG therapy in anti-Ro/SSA positive mothers to prevent the development of cardiac NL. If efficacious, it would also provide clinicians a safe and cost-effective option for women at risk of delivering a child with CHB.
    Collections
    • Boston University Theses & Dissertations [6982]


    Boston University
    Contact Us | Send Feedback | Help
     

     

    Browse

    All of OpenBUCommunities & CollectionsIssue DateAuthorsTitlesSubjectsThis CollectionIssue DateAuthorsTitlesSubjects

    Deposit Materials

    LoginNon-BU Registration

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Boston University
    Contact Us | Send Feedback | Help